

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS	16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS	17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS EXPRESS	JUNE 27 08	CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.	

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:50:01 ON 16 MAR 2009

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 15:50:10 ON 16 MAR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAR 2009 HIGHEST RN 1121544-94-2
DICTIONARY FILE UPDATES: 15 MAR 2009 HIGHEST RN 1121544-94-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> E "RO-1724"/CN 25

E1	1	RO-1-5155/CN
E2	1	RO-1-6272/CN
E3	0 -->	RO-1724/CN
E4	1	RO-4-1398 HYDROCHLORIDE/CN
E5	1	RO-4-6861 HYDROCHLORIDE/CN
E6	1	RO-ADP/CN
E7	1	RO-ATP/CN
E8	1	RO-C 0C15/CN
E9	1	RO-CILLIN/CN
E10	1	RO-CON/CN
E11	1	RO-CYCLINE/CN
E12	1	RO-NEET/CN
E13	1	RO-NEET 6E/CN
E14	1	RO-PAPAV/CN

E15	1	RO-PEL/CN
E16	1	RO-SA 605/CN
E17	1	RO-W 6602/CN
E18	1	RO/SSA RIBONUCLEOPROTEIN (HUMAN GENE RORET)/CN
E19	1	RO363 OXALATE/CN
E20	1	RO5-1162/CN
E21	1	ROA1 (SUS SCROFA DOMESTICA)/CN
E22	1	ROACCUTAN/CN
E23	1	ROACCUTANE/CN
E24	1	ROACH AWAY/CN
E25	1	ROACH KILLER A/CN

=> E "RO 1724"/CN 25

E1	1	RO 17-9651/001/CN
E2	1	RO 1722/CN
E3	1 -->	RO 1724/CN
E4	1	RO 1770/CN
E5	1	RO 18-0647/002/CN
E6	1	RO 18-13M/NA/I2/CN
E7	1	RO 18-1675/CN
E8	1	RO 18-2598/CN
E9	1	RO 18-3981/CN
E10	1	RO 18-5075/CN
E11	1	RO 18-5362/CN
E12	1	RO 18-5364/CN
E13	1	RO 18-5881/CN
E14	1	RO 18-6622/CN
E15	1	RO 18-6776/CN
E16	1	RO 18-7419/CN
E17	1	RO 18-7715/CN
E18	1	RO 18-7953/CN
E19	1	RO 18-8093/CN
E20	1	RO 18-8736/CN
E21	1	RO 18893/CN
E22	1	RO 19 830/CN
E23	1	RO 19-0528/CN
E24	1	RO 19-0645/CN
E25	1	RO 19-1400/CN

=> S E3

L1 1 "RO 1724"/CN

=> DIS L1 1 SQIDE

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 77848-04-5 REGISTRY
 CN RO 1724 (9CI) (CA INDEX NAME)
 MF Unspecified
 CI MAN
 LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER
 DT.CA CAplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 5 REFERENCES IN FILE CA (1907 TO DATE)
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> E "RO 1724"/CN 25

E1	1	RO 17-9651/001/CN
E2	1	RO 1722/CN
E3	1 -->	RO 1724/CN

E4	1	RO 1770/CN
E5	1	RO 18-0647/002/CN
E6	1	RO 18-13M/NA/I2/CN
E7	1	RO 18-1675/CN
E8	1	RO 18-2598/CN
E9	1	RO 18-3981/CN
E10	1	RO 18-5075/CN
E11	1	RO 18-5362/CN
E12	1	RO 18-5364/CN
E13	1	RO 18-5881/CN
E14	1	RO 18-6622/CN
E15	1	RO 18-6776/CN
E16	1	RO 18-7419/CN
E17	1	RO 18-7715/CN
E18	1	RO 18-7953/CN
E19	1	RO 18-8093/CN
E20	1	RO 18-8736/CN
E21	1	RO 18893/CN
E22	1	RO 19 830/CN
E23	1	RO 19-0528/CN
E24	1	RO 19-0645/CN
E25	1	RO 19-1400/CN

=> E "RO 20-1724"/CN 25

E1	1	RO 20-1310/CN
E2	1	RO 20-1344/CN
E3	1 -->	RO 20-1724/CN
E4	1	RO 20-174/CN
E5	1	RO 20-1779/CN
E6	1	RO 20-1815/CN
E7	1	RO 20-1937/CN
E8	1	RO 20-1977/CN
E9	1	RO 20-2230/CN
E10	1	RO 20-2533/CN
E11	1	RO 20-2541/CN
E12	1	RO 20-2926/CN
E13	1	RO 20-3053/CN
E14	1	RO 20-3562/CN
E15	1	RO 20-3600/CN
E16	1	RO 20-3688/CN
E17	1	RO 20-3715/CN
E18	1	RO 20-3760/CN
E19	1	RO 20-5073/CN
E20	1	RO 20-5331/CN
E21	1	RO 20-5331/002/CN
E22	1	RO 20-5397/CN
E23	1	RO 20-5511/CN
E24	1	RO 20-5651/CN
E25	1	RO 20-5720/CN

=> S E3

L2 1 "RO 20-1724"/CN

=> DIS L2 1 SQIDE

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN

RN 29925-17-5 REGISTRY

CN 2-Imidazolidinone, 4-[(3-butoxy-4-methoxyphenyl)methyl]- (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN 2-Imidazolidinone, 4-(3-butoxy-4-methoxybenzyl)- (8CI)

OTHER NAMES:

CN 4-(3-Butoxy-4-methoxy benzyl)-2-imidazolidinone

CN 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidone
 CN DL-4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone
 CN R 020-1724
 CN Ro 20-1724
 CN Ro 20-174
 CN Roche 20-1724
 DR 34185-37-0, 391936-33-7
 MF C15 H22 N2 O3
 LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS,
 CASREACT, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT,
 IFIUDB, IPA, MEDLINE, PHAR, RTECS*, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 DT.CA CAplus document type: Conference; Journal; Patent
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
 PREP (Preparation); PRP (Properties); RACT (Reactant or reagent); USES
 (Uses)
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
 study); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
 study); PROC (Process); PRP (Properties); RACT (Reactant or reagent);
 USES (Uses)
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
 study); PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

412 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 412 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> E "RO 20-1724"/CN 25
 E1 1 RO 20-1310/CN
 E2 1 RO 20-1344/CN
 E3 1 --> RO 20-1724/CN
 E4 1 RO 20-174/CN
 E5 1 RO 20-1779/CN
 E6 1 RO 20-1815/CN
 E7 1 RO 20-1937/CN
 E8 1 RO 20-1977/CN
 E9 1 RO 20-2230/CN
 E10 1 RO 20-2533/CN
 E11 1 RO 20-2541/CN
 E12 1 RO 20-2926/CN
 E13 1 RO 20-3053/CN
 E14 1 RO 20-3562/CN
 E15 1 RO 20-3600/CN
 E16 1 RO 20-3688/CN
 E17 1 RO 20-3715/CN
 E18 1 RO 20-3760/CN
 E19 1 RO 20-5073/CN

E20	1	RO 20-5331/CN
E21	1	RO 20-5331/002/CN
E22	1	RO 20-5397/CN
E23	1	RO 20-5511/CN
E24	1	RO 20-5651/CN
E25	1	RO 20-5720/CN

=> E "ROLIPRAM"/CN 25

E1	1	ROLINOSE/CN
E2	1	ROLIPOLTIDE/CN
E3	1 -->	ROLIPRAM/CN
E4	1	ROLIPRAM-NALTREXONE MIXT./CN
E5	1	ROLIPRAM-SENSITIVE CAMP-SPECIFIC PHOSPHODIESTERASE/CN
E6	1	ROLIPRAM-SENSITIVE CYCLIC AMP PHOSPHODIESTERASE (HUMAN CLONE PHPDEIVD 68,502 MWT) E.C. 3.1.4.17/CN
E7	1	ROLITE LEAD/CN
E8	1	ROLITETRACYCLINE/CN
E9	1	ROLITETRACYCLINE CHLORAMPHENICOL SUCCINATE/CN
E10	1	ROLITETRACYCLINE CITRATE/CN
E11	1	ROLITETRACYCLINE GLUCONATE/CN
E12	1	ROLITETRACYCLINE NITRATE/CN
E13	1	ROLITETRACYCLINE NITRATE HYDRATE/CN
E14	1	ROLITETRACYCLINE-HYDROCHLORIDE/CN
E15	1	ROLIVSAN/CN
E16	1	ROLIVSAN KO/CN
E17	1	ROLIVSAN MV 1/CN
E18	1	ROLIVSAN MV 1, POLYMER WITH (CHLOROMETHYL)OXIRANE, 1,3-ISOBENZOFURANDIONE AND 4,4'-(1-METHYLETHYLIDENE)BIS(PHENOL)/CN
E19	1	ROLIVSAN MV 1, POLYMER WITH 3A,4,7,7A-TETRAHYDROMETHYL-1,3-ISOBENZOFURANDIONE/CN
E20	1	ROLIVSAN TO/CN
E21	1	ROLKLEEN DP 2500E/CN
E22	1	ROLL BONDERITE 103/CN
E23	1	ROLL-FRUCT/CN
E24	1	ROLLANDITE/CN
E25	1	ROLLANDITE (CU3(ASO4)2.4H2O)/CN

=> S E3

L3 1 ROLIPRAM/CN

=> DIS L3 1 SQIDE

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 61413-54-5 REGISTRY
 CN 2-Pyrrolidinone, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]- (CA INDEX NAME)
 OTHER NAMES:
 CN (±)-Rolipram
 CN (R,S)-Rolipram
 CN 4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone
 CN Rolipram
 CN SB 95952
 CN ZK 62711
 DR 85416-74-6
 MF C16 H21 N O3
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
 BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN,
 CSCHEM, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA,
 MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, RTECS*, SYNTHLINE, TOXCENTER,
 USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)


DT.CA CAPlus document type: Conference; Dissertation; Journal; Patent

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); PRPH (Prophetic); RACT (Reactant or reagent); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1188 REFERENCES IN FILE CA (1907 TO DATE)
 22 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1188 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 15:50:01 ON 16 MAR 2009)

FILE 'REGISTRY' ENTERED AT 15:50:10 ON 16 MAR 2009

	E "RO-1724"/CN 25
	E "RO 1724"/CN 25
L1	1 S E3
	E "RO 1724"/CN 25
	E "RO 20-1724"/CN 25
L2	1 S E3
	E "RO 20-1724"/CN 25
	E "ROLIPRAM"/CN 25
L3	1 S E3

=> file medline caplus wpids uspatfull

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	24.12	24.34

FILE 'MEDLINE' ENTERED AT 15:52:30 ON 16 MAR 2009

FILE 'CAPLUS' ENTERED AT 15:52:30 ON 16 MAR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 15:52:30 ON 16 MAR 2009

COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 15:52:30 ON 16 MAR 2009

CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 12 or 13
L4 3096 L2 OR L3

=> s 14 and (CLL or "chronic myelogenous leukemia")
L5 34 L4 AND (CLL OR "CHRONIC MYELOGENOUS LEUKEMIA")

=> s 15 and (prd<19980924 or pd<19980924)
'19980924' NOT A VALID FIELD CODE
1 FILES SEARCHED...
L6 2 L5 AND (PRD<19980924 OR PD<19980924)

=> d 16 1-2 ibib, abs

L6 ANSWER 1 OF 2 MEDLINE on STN
ACCESSION NUMBER: 1998421394 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9746789
TITLE: Type 4 cyclic adenosine monophosphate phosphodiesterase as
a therapeutic target in chronic lymphocytic leukemia.
AUTHOR: Kim D H; Lerner A
CORPORATE SOURCE: Department of Medicine, Section of Hematology and Oncology,
Boston Medical Center, Boston, MA 02118, USA.
SOURCE: Blood, (1998 Oct 1) Vol. 92, No. 7, pp. 2484-94.
Journal code: 7603509. ISSN: 0006-4971.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 199810
ENTRY DATE: Entered STN: 29 Oct 1998
Last Updated on STN: 3 Mar 2000
Entered Medline: 19 Oct 1998

AB Theophylline, a drug known to inhibit several classes of adenosine 3'5'
cyclic monophosphate (cAMP) phosphodiesterases (PDEs), induces apoptosis
in chronic lymphocytic leukemia (CLL) cells. Because the PDE
target for theophylline in CLL remains unknown, we examined the
ability of isoform-specific PDE inhibitors to increase cAMP levels and
induce apoptosis in primary CLL cells. Reverse
transcriptase-polymerase chain reaction of purified CLL cDNA
amplified transcripts for PDE1B, 4A and 4B. The type 4 PDE inhibitor
rolipram but not the type 1 inhibitor vinpocetine increased CLL
cAMP levels. Rolipram-inhibitable (type 4) but not calcium-calmodulin
augmented (type 1) PDE enzyme activity was detected in CLL
samples. In samples from 13 of 14 CLL patients, rolipram
induced apoptosis in a dose-dependent fashion over a 48-hour period.
Interleukin-2 (IL-2)-cultured whole mononuclear cells (WMC) and anti-Ig
stimulated CD19(+) B cells were resistant to the induction of apoptosis by
rolipram while unstimulated CD19(+) B cells, which had a high basal
apoptotic rate, were more sensitive. Rolipram stimulated elevations in
cAMP levels in all four of these cell populations, suggesting that they
differed in sensitivity to cAMP-induced apoptosis. Consistent with this
hypothesis, incubation with the cell permeable cAMP analog dibutyryl-cAMP
induced apoptosis in CLL cells and unstimulated B cells but not
in IL-2-cultured WMC or anti-Ig stimulated B cells. These data identify
PDE4 as a family of enzymes whose inhibition induces apoptosis in
CLL cells.

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:646421 CAPLUS
DOCUMENT NUMBER: 130:261
TITLE: Type 4 cyclic adenosine monophosphate
phosphodiesterase as a therapeutic target in chronic

lymphocytic leukemia
AUTHOR(S): Kim, Doo Ho; Lerner, Adam
CORPORATE SOURCE: Department of Medicine, Section of Hematology and
Oncology, Boston Medical Center, Boston, MA, 02118,
USA
SOURCE: Blood (1998), 92(7), 2484-2494
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: W. B. Saunders Co.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Theophylline, a drug known to inhibit several classes of adenosine 3'5' cyclic monophosphate (cAMP) phosphodiesterases (PDEs), induces apoptosis in chronic lymphocytic leukemia (CLL) cells. Because the PDE target for theophylline in CLL remains unknown, the authors examined the ability of isoform-specific PDE inhibitors to increase cAMP levels and induce apoptosis in primary CLL cells. Reverse transcriptase-polymerase chain reaction of purified CLL cDNA amplified transcripts for PDE1B, 4A and 4B. The type 4 PDE inhibitor rolipram but not the type 1 inhibitor vinpocetine increased CLL cAMP levels. Rolipram-inhibitable (type 4) but not calcium-calmodulin augmented (type 1) PDE enzyme activity was detected in CLL samples. In samples from 13 of 14 CLL patients, rolipram induced apoptosis in a dose-dependent fashion over a 48-h period. Interleukin-2 (IL-2)-cultured whole mononuclear cells (WMC) and anti-Ig stimulated CD19+ B cells were resistant to the induction of apoptosis by rolipram while unstimulated CD19+ B cells, which had a high basal apoptotic rate, were more sensitive. Rolipram stimulated elevations in cAMP levels in all four of these cell populations, suggesting that they differed in sensitivity to cAMP-induced apoptosis. Consistent with this hypothesis, incubation with the cell permeable cAMP analog dibutyryl-cAMP induced apoptosis in CLL cells and unstimulated B cells but not in IL-2-cultured WMC or anti-Ig stimulated B cells. These data identify PDE4 as a family of enzymes whose inhibition induces apoptosis in CLL cells.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:50:01 ON 16 MAR 2009)

FILE 'REGISTRY' ENTERED AT 15:50:10 ON 16 MAR 2009

E "RO-1724"/CN 25
E "RO 1724"/CN 25
L1 1 S E3
E "RO 1724"/CN 25
E "RO 20-1724"/CN 25
L2 1 S E3
E "RO 20-1724"/CN 25
E "ROLIPRAM"/CN 25
L3 1 S E3

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:52:30 ON 16 MAR 2009

L4 3096 S L2 OR L3
L5 34 S L4 AND (CLL OR "CHRONIC MYELOGENOUS LEUKEMIA")
L6 2 S L5 AND (PRD<19980924 OR PD<19980924)

=> s type(A)4(A)PDE(A)inhibitor

L7 35 TYPE(A) 4(A) PDE(A) INHIBITOR

```

=> s type(A)4(A)phosphodiesterase(A)inhibitor
L8      201 TYPE(A) 4(A) PHOSPHODIESTERASE(A) INHIBITOR

=> s phosphodiesterase(A)type(A)4(A)inhibitor
L9      145 PHOSPHODIESTERASE(A) TYPE(A) 4(A) INHIBITOR

=> s 17 and 18 and 19
L10     11 L7 AND L8 AND L9

=> s 17 or 18 or 19
L11     223 L7 OR L8 OR L9

=> dup rem 111
PROCESSING COMPLETED FOR L11
L12     152 DUP REM L11 (71 DUPLICATES REMOVED)

=> s 112 and (CLL or "chronic myelogenous leukemia")
L13     7 L12 AND (CLL OR "CHRONIC MYELOGENOUS LEUKEMIA")

=> d 113 1-7 ibib, abs

```

```

L13  ANSWER 1 OF 7      MEDLINE on STN
ACCESSION NUMBER:      2001540740      MEDLINE
DOCUMENT NUMBER:       PubMed ID: 11587214
TITLE:                 Phosphodiesterase type 4
                        inhibitor suppresses expression of anti-apoptotic
                        members of the Bcl-2 family in B-CLL cells and
                        induces caspase-dependent apoptosis.
AUTHOR:                Siegmund B; Welsch J; Loher F; Meinhardt G; Emmerich B;
                        Endres S; Eigler A
CORPORATE SOURCE:      Division of Clinical Pharmacology, Medizinische Klinik
                        Innenstadt, Klinikum of the Ludwig-Maximilians-University
                        Munich, Germany.
SOURCE:                Leukemia : official journal of the Leukemia Society of
                        America, Leukemia Research Fund, U.K, (2001 Oct) Vol. 15,
                        No. 10, pp. 1564-71.
                        Journal code: 8704895. ISSN: 0887-6924.
PUB. COUNTRY:          England: United Kingdom
DOCUMENT TYPE:          Journal; Article; (JOURNAL ARTICLE)
                        (RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE:              English
FILE SEGMENT:          Priority Journals
ENTRY MONTH:           200202
ENTRY DATE:            Entered STN: 8 Oct 2001
                        Last Updated on STN: 23 Feb 2002
                        Entered Medline: 22 Feb 2002

```

```

AB  B cell chronic lymphocytic leukemia (B-CLL) is an incurable
    clonal disease which shows initial responsiveness to a number of
    chemotherapeutic drugs. However, in most patients the disease becomes
    resistant to treatment. Rolipram, a specific inhibitor of
    phosphodiesterase (PDE) type 4, the PDE predominantly expressed in B-
    CLL cells, has been shown to induce cAMP-dependent apoptosis in
    these cells. In the present study, we demonstrate that the extent of
    rolipram-induced apoptosis is similar to fludarabine-induced apoptosis in
    vitro. The combination of rolipram and fludarabine results in an
    enhancement in the number of apoptotic cells compared to apoptosis induced
    by either agent alone. Second, rolipram suppresses the expression of
    anti-apoptotic members of the Bcl-2 family and induces the pro-apoptotic
    protein Bax, thereby shifting the balance between pro- and anti-apoptotic
    members of the Bcl-2 family towards a pro-apoptotic direction. Finally
    rolipram-induced apoptosis is caspase-dependent. PDE 4 inhibitors are
    currently under investigation for chronic obstructive pulmonary disease

```

and asthma in phase III clinical trials showing promising results with tolerable side-effects. In conclusion, by inducing apoptosis, by enhancing apoptosis induced by fludarabine, by suppressing Bcl-2, Bcl-X and by inducing Bax expression, PDE 4 inhibitors may add a new therapeutic option for patients with B-CLL.

L13 ANSWER 2 OF 7 MEDLINE on STN
 ACCESSION NUMBER: 1998421394 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 9746789
 TITLE: Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia.
 AUTHOR: Kim D H; Lerner A
 CORPORATE SOURCE: Department of Medicine, Section of Hematology and Oncology, Boston Medical Center, Boston, MA 02118, USA.
 SOURCE: Blood, (1998 Oct 1) Vol. 92, No. 7, pp. 2484-94.
 Journal code: 7603509. ISSN: 0006-4971.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LANGUAGE: English
 FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
 ENTRY MONTH: 199810
 ENTRY DATE: Entered STN: 29 Oct 1998
 Last Updated on STN: 3 Mar 2000
 Entered Medline: 19 Oct 1998

AB Theophylline, a drug known to inhibit several classes of adenosine 3'5' cyclic monophosphate (cAMP) phosphodiesterases (PDEs), induces apoptosis in chronic lymphocytic leukemia (CLL) cells. Because the PDE target for theophylline in CLL remains unknown, we examined the ability of isoform-specific PDE inhibitors to increase cAMP levels and induce apoptosis in primary CLL cells. Reverse transcriptase-polymerase chain reaction of purified CLL cDNA amplified transcripts for PDE1B, 4A and 4B. The type 4 PDE inhibitor rolipram but not the type 1 inhibitor vinpocetine increased CLL cAMP levels. Rolipram-inhibitable (type 4) but not calcium-calmodulin augmented (type 1) PDE enzyme activity was detected in CLL samples. In samples from 13 of 14 CLL patients, rolipram induced apoptosis in a dose-dependent fashion over a 48-hour period. Interleukin-2 (IL-2)-cultured whole mononuclear cells (WMC) and anti-Ig stimulated CD19(+) B cells were resistant to the induction of apoptosis by rolipram while unstimulated CD19(+) B cells, which had a high basal apoptotic rate, were more sensitive. Rolipram stimulated elevations in cAMP levels in all four of these cell populations, suggesting that they differed in sensitivity to cAMP-induced apoptosis. Consistent with this hypothesis, incubation with the cell permeable cAMP analog dibutyryl-cAMP induced apoptosis in CLL cells and unstimulated B cells but not in IL-2-cultured WMC or anti-Ig stimulated B cells. These data identify PDE4 as a family of enzymes whose inhibition induces apoptosis in CLL cells.

L13 ANSWER 3 OF 7 USPATFULL on STN
 ACCESSION NUMBER: 2008:58534 USPATFULL
 TITLE: Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms
 INVENTOR(S): Lerner, Adam, Newton, MA, UNITED STATES
 Tiwari, Sanjay, Buchholz, GERMANY, FEDERAL REPUBLIC OF
 PATENT ASSIGNEE(S): Trustees of Boston University, Boston, MA, UNITED STATES, 02215 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080051379	A1	20080228

APPLICATION INFO.: US 2005-792172 A1 20051201 (11)
 WO 2005-US43613 20051201
 20071106 PCT 371 date

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2004-632207P	20041201 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	RONALD I. EISENSTEIN, 100 SUMMER STREET, NIXON PEABODY LLP, BOSTON, MA, 02110, US	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	1456	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to the use of a PDE4 inhibitor and a glucocorticoid to treat peripheral B-cell neoplasms. In particular, the present invention provides a method of treating individuals (e.g. patients) diagnosed with peripheral B-cell leukemias by administering pharmaceutical compositions comprising Type 4 cyclic adenosine monophosphate phosphodiesterase inhibitors and a glucocorticoid. Preferably, the combination of the PDE4 inhibitor and the glucocorticoid has a synergistic effect on apoptosis such that the level of apoptosis induced is greater than the level that would be expected by simply adding a PDE4 inhibitor to a glucocorticoid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2006:315829 USPATFULL
 TITLE: Method of modulating stress-activated protein kinase system
 INVENTOR(S): Blatt, Lawrence M., San Francisco, CA, UNITED STATES
 Seiwert, Scott D., Pacifica, CA, UNITED STATES
 Beigelman, Leonid, San Mateo, CA, UNITED STATES
 Radhakrishnan, Ramachandran, Fremont, CA, UNITED STATES

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 20060270612	A1	20061130
APPLICATION INFO.:	US 2006-431132	A1	20060509 (11)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2005-679471P	20050510 (60)
	US 2005-732230P	20051101 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614, US	
NUMBER OF CLAIMS:	92	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	2814	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are

derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2003:167754 USPATFULL

TITLE: Transgenic animal having a disrupted PDE7A gene and uses thereof

INVENTOR(S): Michaeli, Tamar, Bronx, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030115615	A1	20030619
	US 6740793	B2	20040525
APPLICATION INFO.:	US 2001-950920	A1	20010912 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Craig J. Arnold, Esq., AMSTER ROTHSTEIN & EBENSTEIN, 90 Park Avenue, New York, NY, 10016		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Page(s)		
LINE COUNT:	1270		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a transgenic non-human animal whose genome comprises a disruption in its endogenous PDE7A gene, wherein the transgenic animal exhibits decreased expression of functional PDE7A protein relative to wild-type. The present invention further provides a method for creating a transgenic non-human animal exhibiting decreased expression of functional PDE7A protein relative to wild-type. Finally, the present invention provides a method for screening a PDE7A inhibitor for at least one side-effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2003:24171 USPATFULL

TITLE: Compositions and methods for the treatment of chronic lymphocytic leukemia

INVENTOR(S): Lerner, Adam, Newton Highlands, MA, UNITED STATES

PATENT ASSIGNEE(S): The Trustees of Boston University (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030018014	A1	20030123
APPLICATION INFO.:	US 2002-60759	A1	20020130 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-423349, filed on 1 May 2000, GRANTED, Pat. No. US 6399649 A 371 of International Ser. No. WO 1999-US21518, filed on 17 Sep 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101721P	19980924 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NIXON PEABODY LLP, 101 FEDERAL ST, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	883	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating patients with CLL with pharmaceutical agents are disclosed. The methods of the present invention can be used in patients that have not responded to standard treatment. In addition, the methods can be used to augment the impact of standard chemotherapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2002:129999 USPATFULL
TITLE: Compositions and methods for the treatment of chronic lymphocytic leukemia
INVENTOR(S): Lerner, Adam, Newton Highlands, MA, United States
PATENT ASSIGNEE(S): Boston Medical Center Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6399649	B1	20020604
	WO 2000016621		20000330
APPLICATION INFO.:	US 2000-423349		20000501 (9)
	WO 1999-US21518		19990917
			20000501 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101721P	19980924 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Goldberg, Jerome D.	
LEGAL REPRESENTATIVE:	Nixon Peabody LLP	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	26 Drawing Figure(s); 14 Drawing Page(s)	
LINE COUNT:	901	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating patients with CLL with pharmaceutical agents are disclosed. The methods of the present invention can be used in patients that have not responded to standard treatment. In addition, the methods can be used to augment the impact of standard chemotherapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:50:01 ON 16 MAR 2009)

FILE 'REGISTRY' ENTERED AT 15:50:10 ON 16 MAR 2009

	E "RO-1724"/CN 25
	E "RO 1724"/CN 25
L1	1 S E3
	E "RO 1724"/CN 25
	E "RO 20-1724"/CN 25
L2	1 S E3
	E "RO 20-1724"/CN 25
	E "ROLIPRAM"/CN 25
L3	1 S E3

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:52:30 ON 16 MAR 2009

L4 3096 S L2 OR L3

L5 34 S L4 AND (CLL OR "CHRONIC MYELOGENOUS LEUKEMIA")
 L6 2 S L5 AND (PRD<19980924 OR PD<19980924)
 L7 35 S TYPE(A) 4(A) PDE(A) INHIBITOR
 L8 201 S TYPE(A) 4(A) PHOSPHODIESTERASE(A) INHIBITOR
 L9 145 S PHOSPHODIESTERASE(A) TYPE(A) 4(A) INHIBITOR
 L10 11 S L7 AND L8 AND L9
 L11 223 S L7 OR L8 OR L9
 L12 152 DUP REM L11 (71 DUPLICATES REMOVED)
 L13 7 S L12 AND (CLL OR "CHRONIC MYELOGENOUS LEUKEMIA")

=> s type(N) 4(N) cyclic(N) adenosine(N) monophosphate(N) phosphodiesterase
 L14 22 TYPE(N) 4(N) CYCLIC(N) ADENOSINE(N) MONOPHOSPHATE(N) PHOSPHODIES
 TERASE

=> s l14 and (prd<19980924 or pd<19980924)
 '19980924' NOT A VALID FIELD CODE
 1 FILES SEARCHED...
 L15 3 L14 AND (PRD<19980924 OR PD<19980924)

=> d l15 1-3 ibib, abs

L15 ANSWER 1 OF 3 MEDLINE on STN
 ACCESSION NUMBER: 1998421394 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 9746789
 TITLE: Type 4 cyclic
 adenosine monophosphate
 phosphodiesterase as a therapeutic target in
 chronic lymphocytic leukemia.
 AUTHOR: Kim D H; Lerner A
 CORPORATE SOURCE: Department of Medicine, Section of Hematology and Oncology,
 Boston Medical Center, Boston, MA 02118, USA.
 SOURCE: Blood, (1998 Oct 1) Vol. 92, No. 7, pp. 2484-94.
 Journal code: 7603509. ISSN: 0006-4971.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LANGUAGE: English
 FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
 ENTRY MONTH: 199810
 ENTRY DATE: Entered STN: 29 Oct 1998
 Last Updated on STN: 3 Mar 2000
 Entered Medline: 19 Oct 1998

AB Theophylline, a drug known to inhibit several classes of adenosine 3'5'
 cyclic monophosphate (cAMP) phosphodiesterases (PDEs), induces apoptosis
 in chronic lymphocytic leukemia (CLL) cells. Because the PDE target for
 theophylline in CLL remains unknown, we examined the ability of
 isoform-specific PDE inhibitors to increase cAMP levels and induce
 apoptosis in primary CLL cells. Reverse transcriptase-polymerase chain
 reaction of purified CLL cDNA amplified transcripts for PDE1B, 4A and 4B.
 The type 4 PDE inhibitor rolipram but not the type 1 inhibitor vinpocetine
 increased CLL cAMP levels. Rolipram-inhibitable (type 4) but not
 calcium-calmodulin augmented (type 1) PDE enzyme activity was detected in
 CLL samples. In samples from 13 of 14 CLL patients, rolipram induced
 apoptosis in a dose-dependent fashion over a 48-hour period.
 Interleukin-2 (IL-2)-cultured whole mononuclear cells (WMC) and anti-Ig
 stimulated CD19(+) B cells were resistant to the induction of apoptosis by
 rolipram while unstimulated CD19(+) B cells, which had a high basal
 apoptotic rate, were more sensitive. Rolipram stimulated elevations in
 cAMP levels in all four of these cell populations, suggesting that they
 differed in sensitivity to cAMP-induced apoptosis. Consistent with this
 hypothesis, incubation with the cell permeable cAMP analog dibutyryl-cAMP
 induced apoptosis in CLL cells and unstimulated B cells but not in

IL-2-cultured WMC or anti-Ig stimulated B cells. These data identify PDE4 as a family of enzymes whose inhibition induces apoptosis in CLL cells.

L15 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:646421 CAPLUS
DOCUMENT NUMBER: 130:261
TITLE: Type 4 cyclic
adenosine monophosphate
phosphodiesterase as a therapeutic target in
chronic lymphocytic leukemia
AUTHOR(S): Kim, Doo Ho; Lerner, Adam
CORPORATE SOURCE: Department of Medicine, Section of Hematology and
Oncology, Boston Medical Center, Boston, MA, 02118,
USA
SOURCE: Blood (1998), 92(7), 2484-2494
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: W. B. Saunders Co.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Theophylline, a drug known to inhibit several classes of adenosine 3'5' cyclic monophosphate (cAMP) phosphodiesterases (PDEs), induces apoptosis in chronic lymphocytic leukemia (CLL) cells. Because the PDE target for theophylline in CLL remains unknown, the authors examined the ability of isoform-specific PDE inhibitors to increase cAMP levels and induce apoptosis in primary CLL cells. Reverse transcriptase-polymerase chain reaction of purified CLL cDNA amplified transcripts for PDE1B, 4A and 4B. The type 4 PDE inhibitor rolipram but not the type 1 inhibitor vinpocetine increased CLL cAMP levels. Rolipram-inhibitable (type 4) but not calcium-calmodulin augmented (type 1) PDE enzyme activity was detected in CLL samples. In samples from 13 of 14 CLL patients, rolipram induced apoptosis in a dose-dependent fashion over a 48-h period. Interleukin-2 (IL-2)-cultured whole mononuclear cells (WMC) and anti-Ig stimulated CD19+ B cells were resistant to the induction of apoptosis by rolipram while unstimulated CD19+ B cells, which had a high basal apoptotic rate, were more sensitive. Rolipram stimulated elevations in cAMP levels in all four of these cell populations, suggesting that they differed in sensitivity to cAMP-induced apoptosis. Consistent with this hypothesis, incubation with the cell permeable cAMP analog dibutyryl-cAMP induced apoptosis in CLL cells and unstimulated B cells but not in IL-2-cultured WMC or anti-Ig stimulated B cells. These data identify PDE4 as a family of enzymes whose inhibition induces apoptosis in CLL cells.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2002:206794 USPATFULL
TITLE: Nicotinamide acids, amides, and their mimetics active
as inhibitors of PDE4 isozymes
INVENTOR(S): Magee, Thomas Victor, Mystic, CT, UNITED STATES
Marfat, Anthony, Mystic, CT, UNITED STATES
Chambers, Robert James, Mystic, CT, UNITED STATES
PATENT ASSIGNEE(S): Pfizer Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20020111495	A1	20020815
APPLICATION INFO.:	US 2002-62811	A1	20020131 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-265240P	20010131 (60)
	US 1997-43403P	19970404 (60)

<--

US 1998-105120P 19981021 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49,
NEW YORK, NY, 10017-5612
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 7710

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of the formula: ##STR1##

wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is selected from the partial Formulas: ##STR2##

where q is 1, 2, or 3, W.sup.3 is --O--; --N(R.sup.9)--; or --OC(.dbd.O)--; R.sup.7 is selected from --H; --(C.sub.1-C.sub.6) alkyl, --(C.sub.2-C.sub.6) alkenyl, or --(C.sub.2-C.sub.6) alkynyl substituted by 0 to 3 substituents R.sup.10; --(CH.sub.2).sub.u--(C.sub.3-C.sub.7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R.sup.10; and phenyl or benzyl substituted by 0 to 3 R.sup.14; R.sup.8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is --O--; --S(.dbd.O).sub.t--, where t is 0, 1, or 2; or --N(R.sup.3)--; Y is .dbd.C(R.sup.1.sub.a)--, or --[N(O).sub.k] where k is 0 or 1; R.sup.4, R.sup.5 and R.sup.6 are (1) --H; provided that R.sup.5 and R.sup.6 are not both --H at the same time, --F; --Cl; --(C.sub.2-C.sub.4) alkynyl; --R.sup.16; --OR.sup.16; --S(.dbd.O).sub.pR.sup.16; --C(.dbd.O)R.sup.16, --C(.dbd.O)OR.sup.16, --C(.dbd.O)OR.sup.16; --OC(.dbd.O)R.sup.16; --CN; --NO.sub.2; --C(.dbd.O)NR.sup.16R.sup.17; --OC(.dbd.O)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.O)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.NR.sup.12)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.NCN)NR.sup.16R.sup.16; --NR.sup.12.sub.aC(.dbd.N--NO.sub.2)NR.sup.15R.sup.16; --C(.dbd.NR.sup.12.sub.a)NR.sup.15R.sup.16; --CH.sub.2C(.dbd.NR.sup.12.sub.a)NR.sup.16R.sup.17; --OC(.dbd.NR.sup.12.sub.a)NR.sup.16R.sup.17; --OC(.dbd.N--NO.sub.2)NR.sup.16R.sup.17; --NR.sup.16R.sup.17; --CH.sub.2NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.O)R.sup.16; --NR.sup.12.sub.aC(.dbd.O)OR.sup.16; .dbd.NOR.sup.16; --NR.sup.12.sub.aS(.dbd.O).sub.pR.sup.17; --S(.dbd.O).sub.pNR.sup.16R.sup.17; and --CH.sub.2C(.dbd.NR.sup.12.sub.a)NR.sup.16R.sup.17; (2) --(C.sub.1-C.sub.4) alkyl including dimethyl and --(C.sub.1-C.sub.4)

alkoxy substituted with 0 to 3 substituents --F or --Cl; or 0 or 1 substituent (C.sub.1-C.sub.2) alkoxycarbonyl-, (C.sub.1-C.sub.2) alkylcarbonyl-, or (C.sub.1-C.sub.2) alkylcarbonyloxy-; or (3) an aryl or heterocyclic moiety; or (4) R.sup.5 and R.sup.6 are taken together to form a moiety of partial Formulas (1.3.1) through (1.3.15): ##STR3##

or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s inhibitor(N)PDE4
L16 1973 INHIBITOR(N) PDE4

=> s l16 and (CLL or "chronic myelogenous leukemia")
L17 78 L16 AND (CLL OR "CHRONIC MYELOGENOUS LEUKEMIA")

=> s l17 and (prd<19980924 or pd<19980924)
'19980924' NOT A VALID FIELD CODE
1 FILES SEARCHED...
L18 2 L17 AND (PRD<19980924 OR PD<19980924)

=> d l18 1-2 ibib, abs

L18 ANSWER 1 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2003:265926 USPATFULL

TITLE: Substituted gamma-phenyl-delta-lactams and uses related thereto

INVENTOR(S): Shen, Yaping, Port Coquitlam, CANADA
Burgoyne, David L., Delta, CANADA
Lauener, Ronald W., New Westminster, CANADA
Zhou, Yuanlin, Richmond, CANADA
Rebstein, Patrick J., Vancouver, CANADA
Abraham, Samuel D. M., Vancouver, CANADA

PATENT ASSIGNEE(S): Inflazyme Pharmaceuticals Ltd., Richmond, BC, CANADA,
V6V 2M2 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030186943	A1	20031002
	US 6770658	B2	20040803
APPLICATION INFO.:	US 2002-263336	A1	20021001 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-786949, filed on 11 May 2001, GRANTED, Pat. No. US 6458829 A 371 of International Ser. No. WO 1999-CA819, filed on 9 Sep 1999, UNKNOWN Continuation-in-part of Ser. No. US 2002-81993, filed on 22 Feb 2002, PENDING Continuation of Ser. No. US 2000-527699, filed on 16 Mar 2000, ABANDONED Continuation of Ser. No. US 1999-393445, filed on 8 Sep 1999, ABANDONED		

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-99637P	19980909 (60)	<--
	US 1999-121507P	19990223 (60)	
	US 1999-149517P	19990817 (60)	

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 49

EXEMPLARY CLAIM: 1

LINE COUNT: 6094

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB γ -Phenyl-substituted Δ -lactams are disclosed. They may be formulated into pharmaceutical compositions, and/or used in the treatment or prevention of inflammation or other conditions or disease states.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 2 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2002:254380 USPATFULL

TITLE: Substituted γ -phenyl- Δ -lactones and analogs thereof and uses related thereto

INVENTOR(S): Shen, Yaping, Port Coquitlam, CANADA
Burgoyne, David L., Delta, CANADA
Lauener, Ronald W., Westminister, CANADA
Zhou, Yuanlin, Richmond, CANADA
Rebstein, Patrick J., Vancouver, CANADA
Abraham, Samuel D. M., Vancouver, CANADA

PATENT ASSIGNEE(S): Inflazyme Pharmaceuticals Ltd., Richmond, CANADA
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6458829	B1	20021001
	WO 2000014083		20000316
APPLICATION INFO.:	US 2001-786949		20010511 (9)
	WO 1999-CA819		19990909
			20010511 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-149517P	19990817 (60)
	US 1999-121507P	19990223 (60)
	US 1998-99637P	19980909 (60) <--

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Owens, Amelia
LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC
NUMBER OF CLAIMS: 63
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 5553

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB γ -Phenyl-substituted Δ -lactones and analogs thereof, including lactams, are disclosed. They may be formulated into pharmaceutical compositions, and/or used in the treatment or prevention of inflammation or other conditions or disease states.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:50:01 ON 16 MAR 2009)

FILE 'REGISTRY' ENTERED AT 15:50:10 ON 16 MAR 2009

E "RO-1724"/CN 25

E "RO 1724"/CN 25

L1 1 S E3

E "RO 1724"/CN 25

E "RO 20-1724"/CN 25

L2 1 S E3
E "RO 20-1724"/CN 25
E "ROLIPRAM"/CN 25
L3 1 S E3

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:52:30 ON 16 MAR 2009

L4 3096 S L2 OR L3
L5 34 S L4 AND (CLL OR "CHRONIC MYELOGENOUS LEUKEMIA")
L6 2 S L5 AND (PRD<19980924 OR PD<19980924)
L7 35 S TYPE(A)4(A)PDE(A)INHIBITOR
L8 201 S TYPE(A)4(A)PHOSPHODIESTERASE(A)INHIBITOR
L9 145 S PHOSPHODIESTERASE(A)TYPE(A)4(A)INHIBITOR
L10 11 S L7 AND L8 AND L9
L11 223 S L7 OR L8 OR L9
L12 152 DUP REM L11 (71 DUPLICATES REMOVED)
L13 7 S L12 AND (CLL OR "CHRONIC MYELOGENOUS LEUKEMIA")
L14 22 S TYPE(N)4(N)CYCLIC(N)ADENOSINE(N)MONOPHOSPHATE(N)PHOSPHODIESTE
L15 3 S L14 AND (PRD<19980924 OR PD<19980924)
L16 1973 S INHIBITOR(N)PDE4
L17 78 S L16 AND (CLL OR "CHRONIC MYELOGENOUS LEUKEMIA")
L18 2 S L17 AND (PRD<19980924 OR PD<19980924)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	140.60	164.94
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.64	-1.64

STN INTERNATIONAL LOGOFF AT 16:02:12 ON 16 MAR 2009